Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mescaline Effects and 5-HT2A Receptor Role in Healthy Participants
NCT04849013Phase 1Completed
- Sponsor
- University Hospital Basel
- Start
- Aug 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mescaline (6 arms), sponsored by University Hospital Basel. Primary endpoint: Altered States of Consciousness at 18 months. Started Aug 2021; status: completed.
02
Drugs
mescaline
Beyond the preview
Go deeper on NCT04849013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04849013.